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Oncoproteins Targeting: 
Antibodies, Antisense, Triple-
helix. Case of Anti IGF-I Cancer 
Immunogene Therapy
Jerzy Trojan
Abstract
AFP and IGF-I oncoproteins were introduced as biomarkers for cancer diagno-
sis and targeted in cancer therapy on protein level, but also on transcription and 
translation levels. The protein level was targeted using an injection of antibodies or 
radiolabeled proteins. The transcription and translation levels were targeted by triple 
helix and antisense technologies, respectively. AFP was especially useful for diagno-
sis and therapy of liver cancer, IGF-I was applied in diagnosis and therapy of colon, 
prostate, liver, uterus, ovary and brain tumors. The most spectacular results were 
obtained with IGF-I anti-gene strategy. IGF-I antisense (AS)/triple helix (TH) gene 
therapy was successfully introduced in clinical trial in the USA and Europe. When 
using IGF-I anti-gene therapy, cancer cells provided from biopsies were transfected 
in vitro with IGF-I AS, IGF-I TH expression vectors. A decrease in IGF-I gene 
expression of 80 and 60% was demonstrated when using TH and AS technologies, 
respectively. These transfected cells expressing MHC-I molecules, while injected 
in vivo, induced immune antitumor response mediated by CD8 lymphocytes. The 
median survival of treated glioblastoma patients was 21–22 months. IGF-I AS/TH 
immunogene therapy constitutes one of the most promising approaches in cancer 
therapy, and more specifically when it comes to glioblastoma treatment.
Keywords: cancer, glioma, alpha-fetoprotein, IGF-I, diagnostic, antibodies, 
antisense, triple helix, immunotherapy
1. Introduction
Oncoproteins like alpha-fetoprotein (AFP), serum albumin (AS), and growth 
factors such as GH, IGF, TGF-beta, and EGF are present in embryo-fetal tissues and 
reappear in neoplastic developing tissues, including the central nervous system; this 
concerns especially AFP [1–8] and IGF-I [9–17]. AFP is present in both neural and 
glial developing and cancerous cells, whereas IGF-I is only present in glial developing 
and tumoral cells [10, 18]. This striking difference has helped us orientate a strategy 
to manage the most malignant brain tumor expressing IGF-I gene—glioblastoma.
IGF-I plays an important role in growth as a mediator of growth hormone [19–21]. 
Blocking IGF-I synthesis induces apoptotic and immunogenic phenomena [12, 22]. 
Both phenomena, apoptosis and immunogenicity, related to arrest of IGF-I expression 
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in neoplastic glial cells, were used to prepare antitumor cell vaccines for therapy of 
brain malignant tumor—glioblastoma [12, 23].
An efficient strategy targeting IGF-I was established by construction of vectors 
stopping the synthesis of this oncoprotein on translation and transcription levels: 
vectors expressing either IGF-I antisense RNA or IGF-I RNA forming RNA-DNA 
triple helix, respectively. The glioma cells transfected with these vectors, when 
injected in vivo in animals bearing tumors like glioma or teratocarcinoma or applied 
in clinical treatment of glioblastoma patients, induced an immune antitumor effect 
(CD8+) accompanied by increase of the median survival of patients (successful 
clinical results obtained in the USA, E.U., China) [22, 23].
2. Oncoproteins in diagnostic: AFP and IGF-I
2.1 AFP
AFP is present in normal and neoplastic developing tissues [1, 24–26]. The pres-
ence of AFP seems to be related to the stage of cell and tissue differentiation. AFP is 
absent from either undifferentiated or fully differentiated cells [24].
The localization of AFP was compared with that of another oncoprotein—serum 
albumin, SA. SA-mRNA gave a strong signal in differentiating structures as well 
as in undifferentiated cell clusters. AFP-mRNA was observed only in differentiat-
ing structures; this observation was especially useful in the clinical diagnostic of 
hepatocarcinoma [4, 27].
During an experiment with teratocarcinoma-bearing mice injected intraperi-
toneally with J-125 radiolabeled SA and AFP, significant accumulations of both 
SA and AFP were demonstrated in the tumors, SA being about 3-fold higher 
than that of AFP after normalization to quantity of uptake in liver. In the case of 
comparatively studied neuroblastoma presenting only neuroblastic components 
(different from teratocarcinoma containing both neuroectoblastic and neuroblastic 
elements), the accumulation of radiolabeled SA and AFP showed relationship 1:1. 
External in vivo photo scanning confirmed this relationship of accumulated 
 radiolabeled proteins in both studied tumors; the last observations were useful for 
differential diagnosis of tumors [4, 27–36].
AFP may be used to advantage in radio tracing experiments, since this isologous 
protein is not expected to induce hypersensitivity reactions. On the other hand, and 
contrary to SA, the extremely low serum levels of AFP in adult individuals should 
minimize effects due to competition with endogenous protein. This makes AFP 
a good candidate for tumor biomarker by imaging techniques. The diagnosis and 
therapies of CNS tumors including neuroblastoma are always a subject of discussion 
[36–39].
2.2 IGF-I
Another oncodevelopmental antigen, an insulin like-growth factor, IGF-I  
[20, 40–43], is present in glioma cells but absent in neuroblastoma cells [18]; neuro-
blastic cells express IGF-II [27]. These observations permitted to study separately, 
using IGF-I and IGF-II as the oncoprotein markers, glial and neural tumors [13, 15, 
20, 40–42, 44–46].
Comparative studies of AFP, IGF-I, IGF-II presence in neoplastic cells [3, 4, 18] 
have demonstrated that IGF-I constitutes an essential target for genetic testing. 
IGF-I, similarly to AFP, is involved in tissue development and differentiation, espe-
cially in the development of the nervous system [9, 15, 19, 20, 47–51]. According to 
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Baserga [43], IGF-I is one of the most important growth factors related to normal 
and neoplastic differentiation [50, 52–54].
The elements of IGF-I related transduction pathway (IRS/PI3K-PKC/PDK1/AKT-
Bcl2/GSK3/GS) [55, 56] were also considered as targets for diagnostic [9, 55, 57–66]. 
The relationship between IGF-I and IGF binding proteins are being introduced in 
clinical diagnostics as one of the indicators of precancerous development [67].
IGF-I becomes useful in molecular diagnostic of neonatal CNS malformations 
and tumors [5, 9, 13, 39, 68, 69]. Diagnosis and treatment should logically be 
related, at first using IGF-I gene testing for diagnosis [13, 21, 70], and then targeting 
IGF-I gene through special therapy, such as cancer gene therapy, especially therapy 
of gliomas [11, 22, 71–73].
3. IGF-I and anti-gene immunotherapy
3.1 Protein, translation and transcription levels
To target an oncoprotein directly on protein level, the strategy of antibodies was 
explored. Cancers treated by use of antibodies was in general not efficient.
The treatment of any cancer, especially hepatocarcinoma, demands a permanent 
perfusion, per vena porta, of anti AFP antibodies. The arrest of perfusion has pro-
duced the reappearance of cancer. Similar observation has been made when using 
antibodies against growth factors.
The only possibility was to stop the synthesis of the oncoprotein on the transla-
tion or on the transcription level of the concerned gene, and directly in the cancer 
cells. This hypothesis and our knowledge of chemistry was an epistemological 
problem, pointed out by Mosquera “how to integrate the knowledge of chemistry 
with technique” [74].
As to glioma malignant tumor, glioblastoma (the mortality remains close to 
100%), new or proposed therapies are based generally either on immune treatment 
or on immuno-gene strategies [75, 76]. In order to define new therapies, the differ-
ent techniques for inhibitors [9], and the anti-gene strategy (either antisense, AS, or 
triple helix, TH, approaches) were investigated [61] (Figure 1).
The AS technology [77, 78] has permitted us to establish new and successful 
gene therapy strategies targeting glioma’s growth factors [11, 79] and have now been 
introduced into clinical trials. Other recently introduced technologies include those 
of triple helix, TH [80–83], as well as potentially useful siRNA [84, 85] and miRNA 
(microRNA) [82, 83, 86, 87]. The role of 21–23 mer double-stranded RNA (siRNA) 
in the silencing of genes is strongly similar to that of the TH DNA mechanism, 
which also involves 23 mer RNA [81]. Whether or not siRNA technology or miRNA 
knockdown will supplant the AS and TH oligodeoxynucleotide approaches remains 
in question at this time [83, 85, 87–90]. AS methodology is currently being stan-
dardized to be largely used in clinical trials [18, 89].
As to TH strategy, the oligonucleotides are targeted to double stranded DNA 
containing polypurine-polypyrimidine sequences that readily form triple helixes. 
The studies of triple helix strategy have shown that an RNA strand containing a 
23-nucleotide (nt) oligopurine sequence [80, 86, 87] may be capable of forming 
triple helix structures with an oligopurine-oligopyrimidine sequence of the IGF-I 
gene as well in cultured rat C6 glioma as in rat CNS-1 glioma, and in mouse PCC-4 
cells [86]. Although we cannot exclude other mechanisms, triple helix formation 
remains the most plausible possibility for the inhibition of IGF-I gene expression 
[86]. The arrest of IGF-I synthesis suggests that the RNA strand, which forms the 
triple helix, has inhibited gene transcription in glioma cells.
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3.2 Antisense and triple helix experimental studies
In our experimental studies, we have shown that in IGF-I “antisense” and “triple 
helix” transfected CNS-1 rat glioma cells, PCC-4 mouse embryonal carcinoma cells, 
and in primary human glioma cells, changes in immunogenic properties and apop-
tosis occur. The induction of IGF-I triple helix forming structure, similarly to IGF-I 
antisense approach, was followed by enhanced expression of MHC-I and B-7 [5, 18, 
90–95] and loss of in vivo tumorigenicity. An extensive lymphocytic CD8 positive 
infiltration 4–5 days after injection of AS transfected glioma, teratocarcinoma and 
hepatoma cells into the respective animal bearing tumors was demonstrated [11, 27, 96]. 
These properties were used for selection of human glioma cells that were used in 
IGF-I antisense/triple helix immunogene therapy [90] (Figure 2).
In this context, antigenic peptides presented by class I MHC molecules were 
necessary but, in general, not sufficient to stimulate T cell response. In the absence 
of B-7 molecule, MHC-peptide complexes could selectively inactivate T-cells [97]. 
(Although “triple helix” cells as compared to “antisense” cells show slightly higher 
expression of MHC-I and B7 there are no qualitative immunogenic and apoptotic 
differences between IGF-I “antisense” and “triple helix” approaches).
The absence of IGF-I synthesis in AS and TH transfected cells, could lead to a 
higher level of IGF-I receptor and hence to greater tyrosine kinase content [98]. 
There is a relation between the signal transduction pathway of tyrosine kinase and 
induction of B-7 molecules: enhancement in B-7 co-stimulation through a cAMP 
mechanism linked to tyrosine kinase of the CD 28 receptor has been previously 
reported [99]. Similar signaling through the tyrosine kinase activity of the IGF-I 
receptor shows that: tyrosine kinase activates IRS-1 (Insulin receptor substrate-1), 
Figure 1. 
Schema of technologies suppressing the expression of oncoproteins, including growth factors, GF: antibodies, 
antisense and triple helix. In antibodies technology, the GF expression is directly blocked by its ligand—antibody. 
In antisense technology, the end result is the inhibition of GF mRNA (sense RNA) activity by binding to the 
antisense RNA. In triple helix technology, the oligopurine third strand (23 bp) forms RNA-DNA triple helix 
with GF gene.
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and then IRS-1 activates PI3K (phosphatidylinositol 3 kinase) [100, 101]. This 
mechanism could be considered in the cytokine induced B7–1 expression demon-
strated in fetal human microglia in culture [102].
In the AS and TH transfected cells, IGF-I-R activated by its ligand plays a very 
protective role in programmed cell death, and that this protection is even more 
striking in vivo than in vitro [103]. Apoptosis could play a specific role in our strate-
gies; the phenotypic modifications due to apoptosis may explain the recognition of 
the transfected cells by the immune system like tumor-specific immunity mediated 
by CD8+ T [11, 98]. Apoptotic cells, in the context of MHC-I are recognized by den-
dritic cells activating lymphocytes T-CD8 [104, 105]. B-7 molecules can be included 
in this mechanism, because both MHC-I and B-7 molecules are necessary for T cell 
activation [16, 27, 36, 91, 106–108].
While working on mouse hepatoma cells transfected by the IGF-I triple helix 
approach, we have observed a decrease of cytokines such as Il-10, which is a strong 
immunosuppressor [109], and TNF-alpha, which can act as a factor stimulating 
tumor growth [110, 111]. Moreover, we have found increased levels of TAP 1 and 
2 in these cells. The relationship between the immune process, related to the MHC-I 
or HLA system [112, 113], and the apoptotic process is under study.
3.3 Anti-gene clinical therapy
In the clinical trial using anti-gene IGF-I therapy after subcutaneous vaccina-
tion, the subject developed peri-tumor necrosis; the tissue section bordering the 
necrotic tumor tissue showed infiltration of lymphocytes consisting of both CD4 
and CD8 T cells [114]. Other results concerning peripheral blood lymphocytes 
(PBL) of glioblastoma patients treated by IGF-I triple helix immuno-gene therapy 
show eminent changes in CD8 T cells, especially after second injection. There was 
also an increase in the percentage of CD8 with characteristics switching from CD8+ 
Figure 2. 
Schema of cancer immunogene therapy. The cells isolated from tumor biopsy are growing in tissue culture. The 
established cell line is transfected by vector of anti-gene type (antisense and triple helix IGF-I). The transfected 
cells, and originated apoptotic cells, are injected in proportion 50–50 (“vaccine”) in the cancer patients. The 
presence of MHC-I and B7 molecules present in transfected tumor cells induce an immune response mediated by 
T lymphocytes. Moreover, APC cells also participate as shown in the immunogene mechanism. The activated T 
lymphocytes destroy as well the vaccine (transfected tumor cells) as a tumor.
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CD11b+ to CD8+ CD11b− phenotype, an alteration that may reflect the enhanced 
activation of T cytotoxic cells in blood. Additionally, as far as prognosis of glioblas-
toma patients is concerned, the patients have survived between 18 and 24 months 
after the first diagnosis. Generally, patients with diagnosed glioblastoma multi-
forme, undergoing surgeries and radiotherapy, survive up to 14 months [22, 113].
Our phase I human cancer clinical trial based on the anti-gene, antisense 
approach, is in progress in the U.S.A, Thailand, Poland and China [107, 114, 115] 
and is in parallel with previously established approaches of glioblastoma treatment 
established by either Culver [116] or by Baserga [65]. Following the same approach, 
different antisense strategies to treat glioma tumors have been recently investigated 
[26, 31, 117, 118], especially in relation to glycogen metabolism [119] in glioma 
cells. (Malignant astrocytes present a high level of glycogen [55]). The therapy of 
gliomas using strategies of growth factors inhibition is in permanent progress. The 
inhibition of the IGF-I receptor using AS technology, and its signaling pathway has 
opened a door for experimental and clinical research in various tumors [9, 14, 15, 
42, 62, 120, 121].
4. Discussion
The use of anti-gene therapy was also effective in another AS approach, 
targeted toward the molecule, TGF-beta [79]. TGF-beta2 plays a role in tumor 
progression by regulating key mechanisms including proliferation, metastasis, 
and angiogenesis. The approach of AS TGF-beta using an AS oligodeoxynucleo-
tide—compound AP 12009, has given satisfactory results [122–124]. AP-12009 
treatment was well tolerated and tumor response has been observed [123]. Two 
patients experienced long-lasting complete tumor remission [124]. In another 
clinical AS TGF-beta study, a phase I clinical trial in grade IV astrocytoma 
(GBM) was performed using autologous tumor cells modified by a AS TGF-beta2 
vector [79]. There were indications of humoral and cellular immunity induced by 
the vaccine [57, 79].
As far as AS TGF-beta therapy of GBM is concerned, the treatment of patients 
with recurrent or refractory malignant (high-grade) glioma, WHO grade III or 
IV has been shown to produce results, similar to results obtained with anti IGF-I 
treatment. The role of peripheral blood mononuclear cells in the immune antitumor 
response, and prolonged survival in both anti TGF beta and anti IGF-I approaches 
was comparatively examined. In the case of TGF-beta, it is also important to men-
tion, that although the first successful clinical results were published in 2006–2008, 
the solid experimental data, using AS technology were obtained in 1994/95 [79], 
which means, that long periods of research on the mechanism of AS TGF-beta and 
AS IGF I are required before achieving significant clinical results, confirming the 
usefulness of gene therapy in cancer treatment [90, 122, 123, 125–130].
In AS IGF-I or AS TGF-beta approaches, immune antitumor response, mediated 
by TCD8 and APC cells, was signaled as a principal mechanism of AS technology 
inhibiting growth factors and their signaling pathway [12, 79]. These cells being 
involved in HS (heat shock) protein mechanism, the inhibition of HS was intro-
duced in clinical trials as a new direction for cancer therapy [131].
More recent clinical successful strategies of gliomas treatment, generally as a 
combination therapy using different types of inhibitors (i.e., imatinib, gefitinib) 
including antibodies (i.e., avastin) targeting growth factors and their receptors 
[132–136], are now focusing on anti-gene strategy, especially on antisense or triple 
helix technologies used alone or combined also with pharmacological treatment. As 
far as antisense and triple helix strategies are compared, the triple helix blockade of 
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growth factor has given better results in vitro and in vivo. But combining both strat-
egies, the final result is most effective—stopping the expression of the oncoproteins 
on translation (AS) and transcription (TH) levels, respectively.
5. Conclusion
Among the new strategies in the efforts to successfully treat GBM, the use of AS 
approach targeting IGF-I, TGF-beta or VEGF, their receptors and their downstream 
transduction signaling elements [9, 137], appears to offer a promising solution. The 
final result of the signal transduction pathway element inhibition is an immune 
response mediated in vivo by lymphocytes T CD8 and APC cells. Using cancer 
immunogene therapy of anti-gene anti IGF-I approach, the median survival of 
treated glioblastoma patients has reached 22–24 months. But the near future in 
treating this group of disorders belongs to a combination of treatment: classical 
surgery, radiotherapy with immunotherapy, pharmacologic therapy, growth factor 
inhibitors, and the use of the antisense/triple helix gene blockade approach target-
ing signal transduction pathway elements of cancer processes [16, 22, 23, 36, 66, 90, 
125, 138–147].
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